In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227-DOTA-Rituximab

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 886-895

  Dahle, Jostein ^a   Krogh, Cecilie ^a   Melhus, Katrine B ^a   Borrebæk, Jørgen ^b   Larsen, Roy H ^a   Kvinnsland, Yngve ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Algeta ASA   (Norway)

^c Nordic Neurolabs   (Norway)

Author keywords

Alpha particle radiation; Lymphoma; Microdosimetry; Radioimmunotherapy; Thorium 227

Indexed keywords

ABSORBED RADIATION; ALPHA-PARTICLE RADIATION; AVERAGE DELAY; AVERAGE NUMBERS; BLOOD POOL; CELL CONCENTRATIONS; CELL-BOUND; IN-VITRO; IN-VIVO; LOW DOSE RATE; LYMPHOMA; LYMPHOMA CELLS; MEAN DOSE; MICRODOSIMETRY; PARTICLE RADIATION; RADIOIMMUNOCONJUGATES; RADIOIMMUNOTHERAPY; SINGLE CELLS; TETRAACETIC ACID; X-RADIATION;

CELL CULTURE; GROWTH KINETICS; RADIOTHERAPY; THORIUM;

CELL MEMBRANES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RITUXIMAB TH 227; RADIOISOTOPE; UNCLASSIFIED DRUG;

ALPHA RADIATION; ARTICLE; CELL GROWTH; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL LINE; MICRODOSIMETRY; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SIZE; CULTURE MEDIA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, B-CELL; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 70349610307     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.062     Document Type: Article

References (14)

1. Sgouros G., Ballangrud A.M., Jurcic J.G., et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 40 (1999) 1935-1946
2. Tolmachev V., Carlsson J., and Lundqvist H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy-availability of suitable radionuclides. Acta Oncol 43 (2004) 264-275
3. Dahle J., Borrebaek J., Jonasdottir T.J., et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 110 (2007) 2049-2056
4. Larsen R.H., Borrebaek J., Dahle J., et al. Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm 22 (2007) 431-437
5. Henriksen G., Bruland O.S., and Larsen R.H. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. Anticancer Res 24 (2004) 101-105
6. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol 33 (2006) 271-279
7. Landsverk K.S., Lyng H., and Stokke T. The response of malignant B lymphocytes to ionizing radiation: Cell cycle arrest, apoptosis and protection against the cytotoxic effects of the mitotic inhibitor nocodazole. Radiat Res 162 (2004) 405-415
8. Vermes I., Haanen C., Steffens-Nakken H., et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184 (1995) 39-51
9. Dahle J., Kaalhus O., Moan J., et al. Cooperative effects of photodynamic treatment of cells in microcolonies. Proc Natl Acad Sci U S A 94 (1997) 1773-1778
10. Nuclide Explorer 2000. Computer program, Institute for Transuranium elements, Karlsruhe, Germany.
11. Kvinnsland Y., Stokke T., and Aurlien E. Radioimmunotherapy with alpha-particle emitters: Microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res 155 (2001) 288-296
12. International Commission on Radiation Units and Measurements. Stopping powers and ranges for protons and alpha particles (1993), ICRU, Bethesda, MD
13. Melhus K.B., Larsen R.H., Stokke T., et al. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: An in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter (227)Th. Cancer Biother Radiopharm 22 (2007) 469-479
14. Dahle J., Bruland O.S., and Larsen R.H. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. Int J Radiat Oncol Biol Phys 72 (2008) 186-192